StockNews.com Upgrades Minerva Neurosciences (NASDAQ:NERV) to Hold

Minerva Neurosciences (NASDAQ:NERV) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday.

Separately, HC Wainwright lowered their target price on shares of Minerva Neurosciences from $11.00 to $7.00 and set a “neutral” rating for the company in a report on Thursday.

Minerva Neurosciences Stock Performance

NERV traded up $0.02 during trading on Thursday, hitting $2.37. 15,458 shares of the company traded hands, compared to its average volume of 17,188. The stock’s 50-day simple moving average is $2.66 and its two-hundred day simple moving average is $5.30. Minerva Neurosciences has a 1 year low of $2.29 and a 1 year high of $13.49.

Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($1.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.31). As a group, sell-side analysts forecast that Minerva Neurosciences will post -3.57 earnings per share for the current fiscal year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.